Display options
Cite
Egert-Schmidt AM, Kolbe JM, Mussler S, et al. Patients' compliance with different administration routes for allergen immunotherapy in Germany. Patient Prefer Adherence. 2014;8:1475-81doi: 10.2147/PPA.S70326.
Egert-Schmidt, A. M., Kolbe, J. M., Mussler, S., & Thum-Oltmer, S. (2014). Patients' compliance with different administration routes for allergen immunotherapy in Germany. Patient preference and adherence, 81475-81. https://doi.org/10.2147/PPA.S70326
Egert-Schmidt, Anne-Marie, et al. "Patients' compliance with different administration routes for allergen immunotherapy in Germany." Patient preference and adherence vol. 8 (2014): 1475-81. doi: https://doi.org/10.2147/PPA.S70326
Egert-Schmidt AM, Kolbe JM, Mussler S, Thum-Oltmer S. Patients' compliance with different administration routes for allergen immunotherapy in Germany. Patient Prefer Adherence. 2014 Oct 24;8:1475-81. doi: 10.2147/PPA.S70326. eCollection 2014. PMID: 25368517; PMCID: PMC4216042.
Copy Download .nbib Format: NLM
Share it on

Patient Prefer Adherence. 2014 Oct 24;8:1475-81. doi: 10.2147/PPA.S70326. eCollection 2014.

Patients' compliance with different administration routes for allergen immunotherapy in Germany.

Patient preference and adherence

Anne-Marie Egert-Schmidt, Jan-Marcel Kolbe, Sabine Mussler, Susanne Thum-Oltmer

Affiliations

  1. Allergopharma GmbH & Co. KG, Reinbek, Germany.

PMID: 25368517 PMCID: PMC4216042 DOI: 10.2147/PPA.S70326

Abstract

BACKGROUND: Allergen immunotherapy (AIT) is the practice of administering gradually increasing quantities of an allergen extract to an allergic subject to ameliorate the symptoms associated with the subsequent exposure to the causative allergen. It is the only treatment that may alter the natural course of allergic diseases. According to AIT guidelines and summary of product characteristics (SmPCs), the treatment should be carried out for at least 3 years. It is controversially discussed whether subcutaneous or sublingual administration routes cause higher patients' compliance.

METHODS: German sales data for different preparations of the allergen manufacturer Allergopharma GmbH & Co. KG were retrospectively evaluated for 5 consecutive years, based on prescriptions per patient: pollen sublingual immunotherapy (SLIT) and high-dose hypoallergenic (allergoid) or unmodified depot pollen and mite preparations for subcutaneous immunotherapy (SCIT). To identify patients' compliance, "completed treatment years" were determined. A completed treatment year was defined by the required number of prescribed allergen preparations according to the recommended dosage scheme given in the respective SmPCs.

RESULTS: Prescription data of 85,241 patients receiving pollen or mite SCIT and 706 patients receiving pollen SLIT were included in this analysis. Patients' compliance for at least 3 treatment years with high-dose hypoallergenic pollen SCIT was higher when administered perennially (60%) compared to preseasonally (27%). Prescriptions for at least 3 years were received from 42% of patients with pollen SCIT and from 45% of patients with mite SCIT. Compliance with SLIT was lowest with only 16% of patients receiving prescriptions for at least 3 treatment years. Children and adolescents were more compliant than adults, independent of whether they received SLIT or SCIT.

CONCLUSION: In general, patients' compliance with SCIT using high-dose hypoallergenic or unmodified depot preparations was higher than with pollen SLIT. Perennial application of SCIT seems to increase compliance in comparison to the preseasonal application. Children and adolescents were most compliant, independent of the preparation applied.

Keywords: compliance; high-dose hypoallergenic preparation; perennial immunotherapy; preseasonal immunotherapy; real-life data; subcutaneous immunotherapy; sublingual immunotherapy

References

  1. Patient Prefer Adherence. 2008 Feb 02;2:247-51 - PubMed
  2. World Allergy Organ J. 2011 Nov;4(11):170-8 - PubMed
  3. Allergy. 2006;61 Suppl 82:1-20 - PubMed
  4. Allergy. 2009 May;64(5):669-77 - PubMed
  5. Allergy. 2005 Jun;60(6):801-7 - PubMed
  6. Clin Ther. 2001 Aug;23(8):1296-310 - PubMed
  7. Med Care. 2007 Jun;45(6):521-8 - PubMed
  8. Dtsch Arztebl Int. 2013 Mar;110(9):148-58 - PubMed
  9. J Allergy Clin Immunol. 2013 Aug;132(2):353-60.e2 - PubMed
  10. J Allergy Clin Immunol. 2011 Oct;128(4):791-799.e6 - PubMed
  11. Allergy. 2008 Aug;63(8):1008-14 - PubMed
  12. Eur Ann Allergy Clin Immunol. 2005 Feb;37(2):69-71 - PubMed
  13. Eur Ann Allergy Clin Immunol. 2007 Apr;39(4):123-6 - PubMed
  14. Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess. 2009;96:289-95; discussion 295 - PubMed
  15. Allergy. 2008 Apr;63 Suppl 86:8-160 - PubMed
  16. Allergy. 2010 May;65(5):668-9 - PubMed
  17. Allergy. 2007 Aug;62(8):943-8 - PubMed
  18. Curr Opin Allergy Clin Immunol. 2011 Jun;11(3):192-9 - PubMed
  19. J Allergy Clin Immunol. 2011 Jan;127(1):18-27; quiz 28-9 - PubMed
  20. Clin Exp Allergy. 2013 Jan;43(1):22-8 - PubMed
  21. Clin Exp Allergy. 2001 Sep;31(9):1392-7 - PubMed
  22. Allergy. 1996 Jun;51(6):430-3 - PubMed
  23. Eur Ann Allergy Clin Immunol. 2012 Jun;44(3):135-40 - PubMed
  24. Curr Med Res Opin. 2011 Apr;27(4):855-61 - PubMed
  25. J Allergy Clin Immunol. 2011 Feb;127(2):502-508.e1-6 - PubMed
  26. Am J Rhinol Allergy. 2013 Jul-Aug;27(4):304-8 - PubMed
  27. Allergy. 2008 Aug;63(8):981-9 - PubMed
  28. J Allergy Clin Immunol. 2010 Sep;126(3):668-9 - PubMed
  29. Allergy. 2006 Feb;61(2):198-201 - PubMed
  30. J Allergy Clin Immunol. 2010 Nov;126(5):942-9 - PubMed

Publication Types